2022 World Conference on Lung Cancer (ePosters)-EP02.04-005. Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

EP02.04-005. Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC

Back to course

Pdf Summary

The preliminary data from the ALK cohort of the NAUTIKA1 study on neoadjuvant alectinib for stage II-III ALK non-small cell lung cancer (NSCLC) is presented in this report. The study aims to explore the efficacy and safety of targeted therapies as neoadjuvant and adjuvant treatment for resectable NSCLC with molecular alterations. The ALK cohort of the study included five patients, all of whom completed 8 weeks of neoadjuvant treatment with alectinib and underwent surgery without delays or major complications. The median time from first neoadjuvant treatment dose to surgery was 61 days, and the median time from last neoadjuvant treatment to surgery was 1 day. All patients had a complete resection (R0 resection rate: 100%) and none had radiographic evidence of disease progression prior to surgery. The most frequently reported adverse events during alectinib neoadjuvant treatment were mostly Grade 1/2, with only one Grade 3 adverse event (increased blood creatine phosphokinase) that resolved upon dose reduction. The study concludes that alectinib is well tolerated and feasible for neoadjuvant treatment in patients with stage II-III ALK NSCLC. Further research is ongoing to assess the major pathologic response rate and other efficacy endpoints in this cohort. This preliminary analysis provides insights into the potential of targeted therapies in the neoadjuvant setting for resectable NSCLC with molecular alterations, although more data is needed to confirm these findings. The NAUTIKA1 study is sponsored by Genentech Ltd. and third-party medical writing assistance was provided by Ashfield MedComms.

Asset Subtitle

Jay M Lee

Meta Tag

Speaker Jay M Lee

Topic Early Stage Non-small Cell Lung Cancer - Systemic Therapy

Keywords

ALK cohort

NAUTIKA1 study

neoadjuvant alectinib

stage II-III ALK non-small cell lung cancer

targeted therapies

resectable NSCLC

molecular alterations

surgery

adverse events

feasible treatment